Skip to content

Connor J Haggarty

4 papers in the library · 34 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults.

Psychopharmacology February 1, 2026 Ana Deutsch, Connor J Haggarty, Gavin N Petrie et al. 1 citation

Stimulant drugs such as methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) can impact neurobiological systems implicated in stress, reward processing, and drug use. Although recent preclinical evidence implicates the endocannabinoid (eCB) system in these processes, little is known about the acute effects of stimulants on eCB levels in humans. The aim of the present study was to...

Low-Dose LSD Alters Early and Late Event-Related Potentials to Emotional Faces.

Psychedelic medicine (New Rochelle, N.Y.) December 1, 2024 Connor J Haggarty, Hanna Molla, James Glazer et al. 2 citations

Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these doses affect emotional processing in the brain. In this study, we tested the effect of a single low dose of LSD (26 µg) compared with placebo on electroencephalogram (EEG) event-related potentials (ERP: N170, P300 and Mismatch Negativity) in healthy...

Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 1, 2024 Conor H. Murray, Joel Frohlich, Connor J Haggarty et al. 30 citations

Neural complexity correlates with one's level of consciousness. During coma, anesthesia, and sleep, complexity is reduced. During altered states, including after lysergic acid diethylamide (LSD), complexity is increased. In the present analysis, we examined whether low doses of LSD (13 and 26 µg) were sufficient to increase neural complexity in the absence of altered states of consciousness. In...

The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli.

The European journal of neuroscience June 1, 2024 Connor J Haggarty, Anya K. Bershad, Mahesh K Kumar et al. 1 citation

The 3,4-methylenedioxymethamphetamine (MDMA) has long been used non-medically, and it is currently under investigation for its potential therapeutic benefits. Both uses may be related to its ability to enhance empathy, sociability, emotional processing and its anxiolytic effects. However, the neural mechanisms underlying these effects, and their specificity to MDMA compared to other stimulants,...